V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330004804 | 330002319 | 1.79 | null | Curative (C) | 2017-03-17 | 2017-03-21 | AML16 DA 3+10 | 02 | N | 330020260 | REGORAFENIB |
| 330004805 | 330002319 | null | 65 | Adjuvant (A) | null | 2014-12-19 | RUXOLITINIB | N | N | 330020260 | TEMOZOLOMIDE |
| 330004806 | 330002319 | null | null | Disease modification (D) | 2013-10-08 | 2013-10-16 | AML 18 TRIAL | N | null | 330020260 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330004807 | 330002320 | 1.75 | 8.4 | Palliative (P) | 2015-02-16 | 2015-03-10 | AML LI-1 Trial | N | N | 330020279 | GEMCITABINE |
| 330004808 | 330002321 | null | 43.1 | null | 2013-11-10 | 2014-02-18 | Hydroxycarbamide | N | N | 330020280 | DOXORUBICIN + IFOSFAMIDE |
| 330004809 | 330002322 | 1.65 | 80.5 | Disease modification (D) | 2013-04-13 | 2013-04-13 | CAPECITABINE + CARBOPLATIN + Cetuximab | 2 | N | 330020293 | VIDE |
| 330004810 | 330007278 | 1.79 | 84.5 | Neo-adjuvant (N) | 2015-03-15 | 2015-04-01 | Doxorubicin + Ifosfamide | N | N | 330020297 | VINCRISTINE |
| 330004811 | 330007278 | 1.73 | 10.7 | Neo-adjuvant (N) | 2018-02-13 | 2018-02-14 | AML17 TRIAL | N | N | 330020297 | GEMCITABINE |
| 330004812 | 330007278 | 1.72 | 89.3 | Not known (9) | null | 2017-11-07 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | N | 330020297 | PEI |
| 330004813 | 330007278 | null | 71.4 | null | 2015-10-12 | 2015-10-13 | CISPLATIN + CYCLO + DOXORUBICIN | null | null | 330020297 | PCV |
| 330004814 | 330007278 | 1.8 | 90 | Not known (9) | 2016-03-29 | 2016-05-17 | PEMBROLIZUMAB | N | N | 330020297 | VIDE |
| 330004815 | 330007278 | 1.72 | 58.2 | Adjuvant (A) | 2013-07-06 | 2013-07-06 | AML17 TRIAL | 2 | null | 330020297 | CAV |
| 330004816 | 330002323 | 0 | 67.4 | Curative (C) | 2016-02-27 | 2016-03-01 | Docetaxel + Gemcitabine with GCSF | N | N | 330020321 | CYTARABINE |
| 330004817 | 330002324 | 1.31 | 24 | Curative (C) | 2014-07-16 | 2014-07-23 | Hydroxycarbamide | null | N | 330020323 | CVP |
| 330004818 | 330002325 | 1.77 | 24.4 | Palliative (P) | 2014-02-12 | 2014-02-20 | Hydroxycarbamide | N | N | 330020324 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 330004819 | 330002325 | 1.69 | 73 | Curative (C) | 2014-08-15 | 2014-08-19 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | N | 330020324 | IMATINIB |
| 330004820 | 330002325 | 1.63 | null | Curative (C) | 2018-01-07 | 2018-01-07 | ALL UKALL 2011 HD MtxA (Protocol M) | N | N | 330020324 | EVEROLIMUS |
| 330004821 | 330002326 | 1.82 | 30.4 | Palliative (P) | 2013-10-23 | 2013-10-25 | FCiSt | N | N | 330020341 | NILOTINIB |
| 330004822 | 330002326 | 0.02 | 78.4 | Palliative (P) | 2016-09-22 | 2016-10-08 | CETUXIMAB + CISPLATIN + FU | N | Y | 330020341 | LIPOSOMAL DAUNORUBICIN |
| 330004823 | 330002326 | 0 | 89.7 | Neo-adjuvant (N) | 2016-12-25 | 2016-12-25 | ESHAP | 1 | N | 330020341 | CARBOPLATIN + PEMETREXED |
| 330004824 | 330002327 | 1.55 | 10.4 | Curative (C) | 2017-04-19 | 2017-04-20 | UKALL XII Induction Phase 1 | 02 | N | 330020348 | BORTEZOMIB |
| 330004825 | 330002328 | 1.5 | 52.7 | Not known (9) | 2015-04-23 | 2015-04-26 | BUSULFAN + MELPHALAN | 1 | N | 330020357 | METHOTREXATE |
| 330004826 | 330002329 | 1.77 | 82 | Adjuvant (A) | null | 2015-03-24 | LIPOSOMAL DAUNORUBICIN | N | null | 330020376 | BENDAMUSTINE |
| 330004827 | 330002329 | null | 8.7 | null | 2013-06-07 | 2013-05-23 | FLUOROURACIL + MITOMYCIN + RT | null | null | 330020376 | FLUOROURACIL + MITOMYCIN |
| 330004828 | 330002330 | 1.8 | 72.6 | Curative (C) | 2016-08-15 | 2016-09-15 | CARBOPLATIN + RT | N | Y | 330020383 | AML17 TRIAL |
| 330004829 | 330002330 | null | 43.8 | Neo-adjuvant (N) | 2017-06-02 | 2017-06-06 | CHOP | 2 | N | 330020383 | PEMBROLIZUMAB |
| 330004830 | 330002331 | null | 49.1 | Curative (C) | 2014-09-05 | 2014-09-12 | Cyclophosphamide oral | null | N | 330020388 | HYDROXYCARBAMIDE |
| 330004831 | 330002332 | null | 46.05 | null | null | 2012-08-08 | CARBOPLATIN + RT | null | null | 330020395 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330004832 | 330002332 | 1.6 | 121.9 | Curative (C) | 2014-02-10 | 2014-02-10 | RUXOLITINIB | N | N | 330020395 | DOXORUBICIN + OLARATUMAB |
| 330004833 | 330002333 | null | 15 | Palliative (P) | null | 2014-01-21 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | N | 330020406 | VINBLASTINE |
| 330004834 | 330007284 | null | null | Neo-adjuvant (N) | null | 2016-04-27 | Bortezomib + CYCLOPHOSPHAMIDE + LENALIDOMIDE | Y | N | 330020409 | CHOP |
| 330004835 | 330007284 | 1.62 | 43.7 | Palliative (P) | 2017-12-08 | 2017-12-13 | Bortezomib + CYCLOPHOSPHAMIDE + LENALIDOMIDE | N | N | 330020409 | HYDROXYCARBAMIDE |
| 330004836 | 330002334 | 1.64 | 102.5 | Palliative (P) | 2015-09-15 | 2015-09-23 | Vincristine (weekly) | 02 | N | 330020412 | FEC |
| 330004837 | 330002335 | null | 84.4 | Curative (C) | 2017-10-24 | 2017-10-29 | Cetuximab +Cisplatin + FU (Cycle 1) | N | N | 330020417 | AZACITIDINE |
| 330004838 | 330002335 | 1.71 | 98.7 | Curative (C) | 2015-09-25 | 2015-09-25 | Chlorambucil | 02 | N | 330020417 | CAV |
| 330004839 | 330002335 | 1.51 | null | Not known (9) | 2013-06-03 | 2014-03-01 | EDP + MITOTANE | N | N | 330020417 | UKALL2011 |
| 330004840 | 330002336 | 1.56 | 71.4 | Palliative (P) | 2018-02-23 | 2018-02-27 | Paclitaxel 80mg/m2 day 1 8 15 | Y | N | 330020433 | METHOTREXATE |
| 330004841 | 330007286 | 1.67 | null | Adjuvant (A) | 2018-01-01 | 2018-01-15 | METHOTREXATE | N | N | 330020434 | DOCETAXEL + GEMCITABINE |
| 330004842 | 330007286 | 1.64 | 58 | null | 2016-04-06 | 2016-04-07 | CNS LGG 2004 03 vinc weekly+ carbo | 02 | N | 330020434 | CISPLATIN + TOPOTECAN |
| 330004843 | 330011436 | 1.7 | 61.6 | Palliative (P) | null | 2014-07-06 | Etoposide + Ifosfamide (3 days) | N | N | 330020457 | ENZALUTAMIDE |
| 330004845 | 330002338 | 1.82 | 80.6 | Disease modification (D) | 2018-05-21 | 2018-05-21 | CHOP R - 21 days | 2 | N | 330020476 | ACE (GERM CELL) |
| 330004846 | 330002339 | null | 16.3 | Curative (C) | 2014-05-04 | 2014-05-04 | Capecitabine (21days) + Carboplatin | N | N | 330020482 | CYTARABINE |
| 330004847 | 330007287 | 1.82 | 54.8 | Adjuvant (A) | 2016-11-29 | 2016-11-29 | PEMBROLIZUMAB | 02 | N | 330020490 | CARBOPLATIN + PEMETREXED |
| 330004848 | 330007287 | 1.85 | 83.4 | Palliative (P) | null | 2015-02-22 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | null | null | 330020490 | ETOPOSIDE |
| 330004849 | 330002340 | 1.75 | null | Disease modification (D) | null | 2017-03-06 | Alemtuz+Fludara+Melphalan RIC MUD | null | null | 330020497 | CHLORAMBUCIL |
| 330004850 | 330002340 | 1.5 | null | Palliative (P) | null | 2016-10-28 | Carboplatin + Docetaxel | null | null | 330020497 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330004851 | 330002340 | 1.63 | 50 | Palliative (P) | 2017-08-23 | 2017-08-27 | CNS Low Grade Glioma Vinblastine | 02 | N | 330020497 | CETUXIMAB + CISPLATIN + FU |
| 330004852 | 330002341 | 1.61 | 58 | Neo-adjuvant (N) | 2015-08-19 | 2015-08-20 | TCF | 2 | Y | 330020504 | BEP |
| 330004853 | 330002342 | null | 14 | Disease modification (D) | 2017-11-26 | 2017-11-30 | FCR | 02 | n | 330020508 | CAPECITABINE + CARBOPLATIN |
| 330004854 | 330002342 | 1.62 | 74.35 | Palliative (P) | null | 2016-05-12 | Bevacizumab+Carbo+Gemcitabine | N | N | 330020508 | LOMUSTINE |